Cel-Sci (NYSEAMERICAN:CVM) Trading Up 0.6% – Here’s Why

Cel-Sci Corporation (NYSEAMERICAN:CVM)’s share price rose 0.6% during mid-day trading on Monday . The stock traded as high as $1.75 and last traded at $1.67. 109,559 shares changed hands during mid-day trading, a decline of 8% from the average session volume of 118,831 shares. The stock had previously closed at $1.66.

Cel-Sci Price Performance

The company has a market cap of $29.37 million, a price-to-earnings ratio of -0.17 and a beta of 0.61. The company has a current ratio of 1.48, a quick ratio of 1.42 and a debt-to-equity ratio of 0.35. The business has a 50-day moving average price of $1.45 and a 200 day moving average price of $2.04.

Cel-Sci (NYSEAMERICAN:CVM) last issued its earnings results on Friday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter.

Institutional Trading of Cel-Sci

A hedge fund recently raised its position in Cel-Sci stock. Renaissance Technologies LLC raised its position in shares of Cel-Sci Corporation (NYSEAMERICAN:CVM) by 133.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,890 shares of the company’s stock after buying an additional 20,484 shares during the quarter. Renaissance Technologies LLC owned 0.42% of Cel-Sci worth $115,000 at the end of the most recent quarter. Institutional investors and hedge funds own 12.08% of the company’s stock.

About Cel-Sci

Cel-Sci Corporation is a biotechnology company focused on developing investigational immunotherapies for cancer and infectious diseases. The company’s lead product candidate is Multikine (leukocyte interleukin injection), an immunotherapy designed to stimulate the immune system against cancer. Multikine has primarily been studied as a potential treatment for patients with newly diagnosed, locally advanced primary head and neck cancer before standard surgery, radiation, or chemotherapy.

Cel-Sci also develops therapies using its LEAPS (Ligand Epitope Antigen Presentation System) technology platform.